Medindia

X

Edison Issues ADR Update on Celyad (CYAD)

Tuesday, November 29, 2016 General News J E 4
Advertisement

LONDON, November 29, 2016 /PRNewswire/ --

Celyad has noted that the Phase I safety study on its NKR-2 CAR T-cell autologous therapy produced some "reports of clinical benefit". The THINK Phase Ib trial has been approved in Belgium and awaits FDA clearance. This is a major expansion of CAR therapy with five solid tumors plus AML and MM being explored. As a result, we have raised the probability of success to 20% from 18.5%. There is a challenge to the granted 2009 US patent on allogeneic CAR T-cells. While the claim is being re-examined, the patent remains in force; other patents and patent applications provide protection. Edison's interim indicative value has been rebased and increased to $50 per share, formerly $46 per share.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our valuation model for Celyad has been rebased to focus on NKR-2 indications. As Celyad is initiating an NKR-2 trial in solid tumors, these have also been added to the valuation but with caution as this could be a challenging set of indications and there is very little current clinical data on the NKR-2 product. The C-Cure value is unchanged at 35% probability and is now regarded as an indicative deal value on partnering. Celyad has also cut its cash burn to no more than $34m per year to conserve cash to mid-2019. These adjustments give an interim indicative value of $50 per share, formerly $46 per share.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: John Savin                     Edison Investment Research           +44(0)20-3077-5735 Lala Gregorek                       Edison Investment Research           +44(0)20-3681-2527 healthcare@edisongroup.com

Contact details: Learn more at http://www.edisongroup.co and connect with Edison on:            LinkedIn http://www.linkedin.com/company/edison-investment-research     Twitter  http://www.twitter.com/Edison_Inv_Res     YouTube  http://www.youtube.com/edisonitv     Google+  https://plus.google.com/105425025202328783163/posts

SOURCE Edison Investment Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Research Reports Coverage on Healthcare Stocks -- ...
S
Technical Reports on Biotech Stocks -- Juno Therap...